Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APR003 in advanced colorectal cancer with liver lesions
NCT04645797Phase 1Terminated
- Sponsor
- Apros Therapeutics
- Start
- Jan 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of APR003 in colorectal cancer (CRC), sponsored by Apros Therapeutics. Primary endpoints: Number of Patients With Dose Limiting Toxicities, Maximum Concentration of APR003 and 7 more. Started Jan 2021; status: terminated.
02
Drugs
APR003
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04645797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645797.